Revenue: As of FY2025 Q2, the actual value is USD 1.269 M.EPS: As of FY2025 Q2, the actual value is USD -0.17.EBIT: As of FY2025 Q2, the actual value is USD -2.516 M.<h3>Segment Revenue</h3><ul><li>Diagnostic R&amp;D: No revenue reported for the three months ended June 30, 2025, compared to $4,038 for the same period in 2024. For the six months ended June 30, 2025, no revenue was reported compared to $6,923 in 2024.</li><li>Laboratory Services: Revenue of $1,269,483 for the three months ended June 30, 2025, compared to $2,393,614 in 2024. For the six months ended June 30, 2025, revenue was $3,123,080 compared to $4,797,120 in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended June 30, 2025, was $4,060,787, compared to $2,110,279 in 2024. For the six months ended June 30, 2025, the net loss was $6,721,204, compared to $4,072,094 in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended June 30, 2025, were $3,785,043, compared to $4,485,450 in 2024. For the six months ended June 30, 2025, operating expenses were $8,265,779, compared to $8,837,071 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $4,288,981, compared to $3,878,400 in 2024.</li><li>Net Cash Used in Investing Activities: For the six months ended June 30, 2025, net cash used in investing activities was $64,213, compared to $69,672 in 2024.</li><li>Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $4,050,738, compared to $1,927,813 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to expand commercialization efforts for CyPath® Lung, aiming for a 3X year-over-year revenue increase. The focus is on increasing sales and operational efficiency while reducing costs associated with unprofitable services.</li><li>Non-Core Business: The company is exploring strategic partnerships for its therapeutic discoveries, particularly for topical treatments of skin cancers.</li><li>Priority: The company emphasizes the need for additional capital to support operations and achieve profitability, with a focus on raising funds through equity or debt securities.</li></ul>

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 1.269 M